Regeneron Pharmaceuticals

Executive Summary

Regeneron Pharmaceuticals is a leading biotechnology company with a strong commercial portfolio anchored by Dupixent (dupilumab) and Eylea (aflibercept), which together generate over $15 billion in annual revenue. Dupixent continues to expand its label across multiple type 2 inflammatory indications, while Eylea faces biosimilar competition but benefits from the high-dose Eylea HD formulation. The company's pipeline is one of the deepest in the industry, with over 450 candidates spanning oncology, genetic medicines, and immunology. Key late-stage assets include linvoseltamab (BCMA bispecific antibody for multiple myeloma) and itepekimab (anti-IL-33 for COPD). Regeneron's proprietary VelocImmune platform enables efficient antibody discovery, and its manufacturing capabilities provide a competitive edge. Despite near-term headwinds from Eylea biosimilars, the company's robust pipeline and commercial execution support a positive outlook.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on linvoseltamab for relapsed/refractory multiple myeloma70% success
• Q4 2026Phase 3 data readout for itepekimab in COPD60% success
• Q4 2026Dupixent Phase 3 results in chronic spontaneous urticaria80% success